Skip to main content

Table 5 Late toxicities

From: A phase I dose-escalation trial of stereotactic body radiotherapy using 4 fractions for patients with localized prostate cancer

  Level 1 (n = 9) Level 2 (n = 9) Level 3 (n = 9)
G1 G2 G1 G2 G1 G2
RTOG
 GU 3 (33.3%) 1 (11.1%) 4 (44.4%) 0 (0.0%) 4 (44.4%) 0 (0.0%)
 GI 2 (22.2%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (22.2%) 1 (11.1%)
Micturition pain 0 (0.0%) 0 (0.0%) 1 (11.1%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Frequency 4 (44.4%) 0 (0.0%) 4 (44.4%) 0 (0.0%) 4 (44.4%) 0 (0.0%)
Urinary incontinence 1 (11.1%) 0 (0.0%) 1 (11.1%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Retention 0 (0.0%) 1 (11.1%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Hematuria 0 (0.0%) 0 (0.0%) 1 (11.1%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Stricture 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Proctitis 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (11.1%) 0 (0.0%)
Fecal incontinence 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Diarrhea 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Rectal hemorrhage 2 (22.2%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (11.1%) 1 (11.1%)
  1. GU Genitourinary toxicity, GI Gastrointestinal toxicity, RTOG Radiation therapy oncology group